Search results
H. Michael Shepard (born 1949) is an American cancer researcher who was awarded the 2007 Harvard Medical School Warren Alpert Foundation Prize and the 2019 Lasker Clinical research award, which he shared with Dennis Slamon and Axel Ullrich for their development of Herceptin [1] Education and career.
Dr H. Michael Shepard, PhD. SCIENTIFIC ADVISOR. Biography. After completing a PhD in Cellular, Molecular and Developmental Biology at Indiana University (IU), Bloomington, and then a successful Walter Winchell-Damon Runyon postdoctoral fellowship, also in the Biology Department at IU, Shepard joined Genentech in 1980.
Mar 15, 2024 · In this World View, H. Michael Shepard describes his personal story behind the discovery of trastuzumab, 25 years since its FDA approval for HER2-overexpressing breast cancers.
Sep 24, 2019 · Dr. H. Michael Shepard and his team have identified a critical breast cancer biomarker and developed the drug Herceptin, which can treat more than just breast cancer.
Oct 8, 2019 · Revolutionizing Breast Cancer Treatment: Lasker Award Winner H. Michael Shepard, ’73 B.S. in Zoology. Shepard recently returned to his old stomping grounds in Davis and Sacramento, part of a recent tour to commemorate the Lasker Award. David Slipher/UC Davis.
Dr. H. Michael Shepard is a global, leading authority on cancer research and therapeutics. He is best known for his invention of "Herceptin"/Trastuzumab, which has remained one of the most profitable platforms for Roche ($7B USD).
People also ask
Who is Dr Michael Shepard?
Who is Dr Shepard & how did he become a doctor?
What did John Shepard do at Genentech?
About Mike Shepard. NOTE: Shepard is an adjunct faculty member with the Department of Biology, Indiana University Bloomington. He currently serves as a scientific advisor with Hemogenyx Pharmaceuticals. Faculty profile for H. Michael Shepard.
